Eyenovia Shares Plumb New Depths After Study Failure

Dow Jones01:02

By Colin Kellaher

Eyenovia shares collapsed Friday after a late-stage study of the ophthalmic technology company's proposed treatment for nearsightedness in children failed.

Shares of the New York company were recently changing hands at 9.7 cents, down more than 71%, after touching an all-time low of 8.6 cents earlier in the session.

Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options after an independent review found that the study wouldn't hit its main goal.

Following the disclosure, William Blair downgraded shares of Eyenovia to market perform from outperform, citing the negative study results and the company's capital constraints.

In a research note, analyst Lachlan Hanbury-Brown said that while he still sees value in Eyenovia's pipeline and commercial products, the company had only $7.2 million in cash at the end of the third quarter and no clear path on which to raise more capital on favorable terms, which he said will limit Eyenovia's ability to invest in the launch of its of clobetasol product and realize its potential value.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 15, 2024 12:02 ET (17:02 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483302535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 01:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483302535","market":"us","top_or_hot":-1,"title":"Eyenovia Shares Plumb New Depths After Study Failure","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Eyenovia shares collapsed Friday after a late-stage study of the ophthalmic technology company's proposed treatment for nearsightedness in children failed. \n</p>\n<p>\n  Shares of the New York company were recently changing hands at 9.7 cents, down more than 71%, after touching an all-time low of 8.6 cents earlier in the session. \n</p>\n<p>\n  Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options after an independent review found that the study wouldn't hit its main goal. \n</p>\n<p>\n  Following the disclosure, William Blair downgraded shares of Eyenovia to market perform from outperform, citing the negative study results and the company's capital constraints. \n</p>\n<p>\n  In a research note, analyst Lachlan Hanbury-Brown said that while he still sees value in Eyenovia's pipeline and commercial products, the company had only $7.2 million in cash at the end of the third quarter and no clear path on which to raise more capital on favorable terms, which he said will limit Eyenovia's ability to invest in the launch of its of clobetasol product and realize its potential value. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 15, 2024 12:02 ET (17:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eyenovia Shares Plumb New Depths After Study Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyenovia Shares Plumb New Depths After Study Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 01:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  Eyenovia shares collapsed Friday after a late-stage study of the ophthalmic technology company's proposed treatment for nearsightedness in children failed. \n\n\n  Shares of ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYEN","symbol_name":"Eyenovia Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483302535","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483302535","pubTimestamp":1731690120,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Eyenovia shares collapsed Friday after a late-stage study of the ophthalmic technology company's proposed treatment for nearsightedness in children failed.Shares of the New York company were recently changing hands at 9.7 cents, down more than 71%, after touching an all-time low of 8.6 cents earlier in the session.Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options after an independent review found that the study wouldn't hit its main goal.Following the disclosure, William Blair downgraded shares of Eyenovia to market perform from outperform, citing the negative study results and the company's capital constraints.In a research note, analyst Lachlan Hanbury-Brown said that while he still sees value in Eyenovia's pipeline and commercial products, the company had only $7.2 million in cash at the end of the third quarter and no clear path on whic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYEN":"Eyenovia Inc.","BK4007":"制药"},"translate_title":"研究失败后，Eyenovia股价再创新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYEN":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Eyenovia shares collapsed Friday after a late-stage study of the ophthalmic technology company's proposed treatment for nearsightedness in children failed. \n\n\n  Shares of the New York company were recently changing hands at 9.7 cents, down more than 71%, after touching an all-time low of 8.6 cents earlier in the session. \n\n\n  Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options after an independent review found that the study wouldn't hit its main goal. \n\n\n  Following the disclosure, William Blair downgraded shares of Eyenovia to market perform from outperform, citing the negative study results and the company's capital constraints. \n\n\n  In a research note, analyst Lachlan Hanbury-Brown said that while he still sees value in Eyenovia's pipeline and commercial products, the company had only $7.2 million in cash at the end of the third quarter and no clear path on which to raise more capital on favorable terms, which he said will limit Eyenovia's ability to invest in the launch of its of clobetasol product and realize its potential value. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 12:02 ET (17:02 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483302535"}